CD69 is traditionally known as an early activation marker on T cells, natural killer (NK) cells, and other leukocytes.
Elevated CD69 expression on tumor-infiltrating lymphocytes (TILs) may reflect an ongoing anti-tumor immune response.
CD69 is an early lymphocyte activation marker that plays multifaceted roles in the tumor microenvironment, influencing cell retention, activation, and antitumor immune responses. In various cancers—including melanoma, breast cancer, NSCLC, HNSCC, and hematologic malignancies—the expression of CD69 on tumor-infiltrating immune cells often correlates with an active antitumor response and, in many cases, improved patient prognosis.
(Will delete Record if Target field = "Delete") Home